GSK Signs GMP Consent Decree For Cidra Plant But Avoids Disgorgement Fee
Executive Summary
Good manufacturing practices compliance efforts under GlaxoSmithKline's consent decree with FDA are likely to cost the company significantly less than Schering-Plough's 2002 agreement with the agency
You may also be interested in...
GSK Avandia For Alzheimer’s Could Be “The Most Important Asset” In Pipeline
GlaxoSmithKline's Avandia may become the most important product in the firm's pipeline if Phase III results show the type 2 diabetes drug to be effective at treating Alzheimer's disease, CEO J.P. Garnier said
GSK Avandia For Alzheimer’s Could Be “The Most Important Asset” In Pipeline
GlaxoSmithKline's Avandia may become the most important product in the firm's pipeline if Phase III results show the type 2 diabetes drug to be effective at treating Alzheimer's disease, CEO J.P. Garnier said
GSK’s Avandaryl Approved, But Manufacturing Changes Are Still Pending
GlaxoSmithKline's diabetes line extension product Avandaryl has cleared FDA, but the firm plans to move manufacturing for commercial supply of the drug out of its problematic Puerto Rico plant